Sci Transl Med:环糊精有望治疗动脉粥样硬化

2016-04-15 新华社 郭洋 《科学转化医学》

德国等国研究人员6日在美国《科学转化医学》杂志上报告说,环状低聚糖——环糊精可起到阻止甚至减少胆固醇结晶沉积的作用,有望用于治疗动脉粥样硬化。 动脉粥样硬化是指动脉壁上沉积一层包括胆固醇结晶在内的粥样物质,使动脉弹性降低、管腔变窄,常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应,导致动脉壁出现可致命的炎症。 先前研究发现,环糊精可缓解先天性糖脂代谢性疾病——C型尼曼匹克氏症患者脑

德国等国研究人员6日在美国《科学转化医学》杂志上报告说,环状低聚糖——环糊精可起到阻止甚至减少胆固醇结晶沉积的作用,有望用于治疗动脉粥样硬化。

动脉粥样硬化是指动脉壁上沉积一层包括胆固醇结晶在内的粥样物质,使动脉弹性降低、管腔变窄,常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应,导致动脉壁出现可致命的炎症。

先前研究发现,环糊精可缓解先天性糖脂代谢性疾病——C型尼曼匹克氏症患者脑细胞内的胆固醇运输障碍。德国波恩大学等机构的研究人员据此猜测,环糊精可能有助于清除动脉粥样硬化患者动脉壁上沉积的胆固醇结晶

研究人员持续8周给实验鼠喂食高胆固醇食物,并给一部分实验鼠注射了环糊精。结果显示,实验鼠在注射环糊精后,血管中的沉积物要比其他实验鼠少很多。环糊精提高了细胞清除胆固醇的能力,并减少了血管中的炎症反应。研究人员利用人类动脉粥样硬化患者血管中的沉积物展开的研究也得出上述结论。

研究人员表示,环糊精可用于研发动脉粥样硬化治疗药物。不过,虽然环糊精作为一些难溶性药物的增溶剂早已进入市场,但将其作为治疗动脉粥样硬化的新药还需进一步临床研究。


原始出处:

Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, Skjelland M, De Nardo D, Labzin LI, Kerksiek A, Hempel C, Heneka MT, Hawxhurst V, Fitzgerald ML, Trebicka J, Björkhem I, Gustafsson JÅ, Westerterp M, Tall AR, Wright SD, Espevik T, Schultze JL, Nickenig G, Lütjohann D, Latz E. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med. 2016 Apr 6;8(333):333ra50

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2017-03-10 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2016-04-16 1de7460am01(暂无匿称)

    这就是创新

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2016-04-16 1de3b290m83(暂无匿称)

    中医药

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2016-04-16 Wechat4343a314

    记住环瑚精

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2016-04-16 李继凯

    高大上的文章

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1656700, encodeId=910f1656e00a4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Fri Mar 10 19:47:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067181, encodeId=82c7206e181d0, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Thu Jan 12 10:47:00 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944405, encodeId=70b21944405fa, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Sat Aug 06 08:47:00 CST 2016, time=2016-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606897, encodeId=98e0160689ed3, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 17 09:47:00 CST 2016, time=2016-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78811, encodeId=3fe8e88113f, content=这就是创新, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=225a1697989, createdName=1de7460am01(暂无匿称), createdTime=Sat Apr 16 22:22:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78791, encodeId=1793e879119, content=中医药, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK29w9r0upRgxUXHNhe7bd3VxHnhBSpibMbKOjtX92zXr78SkuZfUNuADrjHiaw6uibZaEYjh9cJLzew/132, createdBy=261e1682638, createdName=1de3b290m83(暂无匿称), createdTime=Sat Apr 16 20:15:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78786, encodeId=79a0e878636, content=记住环瑚精, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Sat Apr 16 19:52:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78760, encodeId=13f1e8760ff, content=高大上的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78761, encodeId=ae81e876135, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Sat Apr 16 17:32:00 CST 2016, time=2016-04-16, status=1, ipAttribution=)]
    2016-04-16 李继凯

    值得关注

    0

相关资讯

两会:霍勇:管好“坏”胆固醇可减少心脑血管疾病的发生

过去几十年,我国应对心脑血管疾病做了很多的努力。目前,高血压筛查及糖尿病管理已经被纳入到我国公共卫生服务中,但是还缺少血脂管理。近日,全国政协委员、北京大学第一医院心内科主任霍勇教授接受新华网采访时表示,我国心血管病患病率仍处于持续上升阶段,基于此严峻的形势,呼吁政府把血脂管理纳入到公共卫生服务当中,“这样才能使我国从总体上控制三高,使心脑血管疾病的发病及死亡率下降”。警惕“坏”胆固醇——低密度脂

“好”胆固醇未必有益健康

“好”胆固醇有益健康?这个说法已有几十年,但一项最新研究显示并不一定是这样。 高密度脂蛋白胆固醇被认为可降低心脏病风险,因而被称为“好”胆固醇。但美国宾夕法尼亚大学等机构研究人员在新一期美国《科学》杂志上发表论文说,“好”胆固醇增多也可能由某种罕见的基因突变引起,在这种情况下心脏病风险反而升高。 胆固醇不能溶解于血液中。通常认为,它须依附在脂蛋白上才能从周边组织进入肝脏,在这里被分解代谢、

NEJM:无心血管疾病的中度危险人群的降压和降脂治疗

血压和低密度脂蛋白(LDL)胆固醇升高增加心血管疾病的风险。降低两者应该可以大幅降低心血管事件的风险。进行了一项2×2的阶乘设计实验,将12705名无心血管疾病的中度危险人群随机分配到瑞托伐他汀(10mg /天)或安慰剂组,和坎地沙坦(16mg/天)+氢氯噻嗪(12.5mg/天)或安慰剂组。分析报道中,我们比较了3180名受试者分配到联合治疗(瑞托伐他汀和两种降压药)以及3168名受试者分配到双安

遗传性高胆固醇血症比预期更加普遍

最新研究表明,因遗传因素发生高胆固醇血症的人数是以前预期数目的两倍。 家族型高胆固醇血症会显著提高早期心肌梗死的风险。研究发现美国每250个人中就有一名该病的患者,而不是以前认为的每500人中有一人。 研究人员之一哈佛医学院儿科副教授Sarah de Ferranti博士表示,这个新的数据不代表这个问题越来越严重了,而是这个问题以前没有被发现。对于有这个潜在致命问题的人来说,尽早持续的预防措施

《科学》揭秘:为什么“好”胆固醇高还会得心脏病?

有过体检经历的人都知道,检测血脂有常规四项:总胆固醇、低密度脂蛋白胆固醇(LDL-c)、高密度脂蛋白胆固醇(HDL-c)和甘油三酯。在人体血液的胆固醇代谢过程中,脂蛋白起到了非常关键的作用。我们比较熟悉的脂蛋白有低密度脂蛋白(LDL)和高密度脂蛋白(HDL)两种。它们都是血液中胆固醇的运载体。LDL与胆固醇结合后,形成LDL-c,LDL-c在血液中容易聚集在动脉壁上,时间久了就引起动脉硬化。所以,

Nature:我国癌症免疫疗法重大发现!调节胆固醇代谢增加T细胞抗肿瘤效应

作为免疫系统的得力干将,T细胞监测肿瘤,并且直接发挥抗肿瘤效应。然而,肿瘤通过肿瘤微环境中的多种机制逃避T细胞攻击。重新激活T细胞的抗肿瘤作用已被证实在治疗多种癌症中具有巨大的临床益处。然而,当前基于T细胞的癌症免疫疗法只在部分病人群体中有疗效。因此,科学家还需要开发出让更多病人受益的癌症免疫疗法。在一项新的研究中,来自中国科学院上海生命科学研究院生物化学与细胞生物学研究所的许琛琦团队和李伯良团队